Full Press Release Details
Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization
across life sciences, food, nutrition and industrial markets
Fla., June 15, 2026 - Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic"
or the "Company"), a biotechnology company focused on the development and commercialization of scalable microbial protein
production platforms, today highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease
preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance
commercial adoption across multiple high-growth markets.
recent Ebola-related preparedness activity has brought renewed attention to one of the most important challenges in global health: the
ability to rapidly manufacture vaccines, monoclonal antibodies and other biologics at sufficient scale and affordable cost. Dyadic believes
its C1 platform is well positioned to help address this challenge through rapid strain development, high expression levels, flexible
microbial manufacturing and reduced production timelines.
C1 platform has demonstrated the ability to progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen
or monoclonal antibody in approximately 15 days. The Company believes this speed may be particularly important during infectious disease
outbreaks, where response time, manufacturing capacity and equitable access can directly affect preparedness outcomes.
outbreaks continue to demonstrate that speed matters," said Mark A. Emalfarb, Chief Executive Officer of Dyadic Applied BioSolutions.
"Scientific discovery alone is not enough. Vaccines and antibody therapies that cannot be manufactured quickly, affordably and
at sufficient scale are unable to reach the people who need them most. A vaccine or antibody that is unavailable or unaffordable is 100%
ineffective. Manufacturing matters."
Preparedness Creates Timely Interest in Rapid Biomanufacturing
Bundibugyo Ebola virus outbreak has led to enhanced surveillance, traveler screening, border monitoring and other public health measures
associated with international travel and large public gatherings, such as the FIFA World Cup. These activities underscore the need for
technologies that can support the rapid development, production and release of vaccines and antibody therapies during infectious disease
is experiencing growing interest in the potential application of its C1 microbial protein production platform for Ebola-related vaccine
antigen and monoclonal antibody development programs. This interest reflects the growing need for technologies that can support rapid,
scalable and cost-effective biologics manufacturing during infectious disease outbreaks.
recently announced collaboration with Scripps Research represents one important track. The collaboration combines Scripps' expertise
in computational antigen design and viral immunology with Dyadic's C1 protein production platform. Together, the organizations
are evaluating approaches that may accelerate the development and production of vaccine antigens and monoclonal antibody candidates for
infectious diseases, including Ebola, hantaviruses and other emerging viral threats.
second track involves research proposals submitted in response to CEPI's Ebola funding call that incorporate Dyadic's C1
platform to support vaccine development and manufacturing. These submissions are focused on evaluating the potential use of C1 to support
rapid vaccine antigen development and scalable manufacturing for Ebola preparedness.
third track involves an additional monoclonal antibody initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub.
This initiative is focused on antibody programs targeting Ebola and hantavirus infections and further highlights the potential application
of Dyadic's C1 platform beyond vaccine antigen production and into scalable monoclonal antibody manufacturing.
these three tracks underscore the growing relevance of Dyadic's C1 platform in infectious disease preparedness, spanning vaccine
antigen development, monoclonal antibody production and scalable biologics manufacturing.
Platform Addresses a Critical Bottleneck: Manufacturing
believes that as artificial intelligence has the potential to accelerate the discovery of new antibodies, antigens, enzymes and other
proteins, scalable manufacturing platforms can play an increasingly important role in converting scientific innovation into real-world
Company believes the C1 platform's rapid strain development, high expression levels, use of standard microbial bioreactors, flexible
manufacturing profile and potential cost advantages can help support regional manufacturing initiatives focused on vaccines, monoclonal
antibodies and other biologics.
collaborations and grants involving organizations such as CEPI, the Gates Foundation, the European Vaccines Hub and Fondazione Biotecnopolo
di Siena, Dyadic continues to advance and further validate its C1 platform. In addition, Dyadic's DYAI-100 clinical study demonstrated
that C1-produced antigens were generally safe and well tolerated, supporting the potential use of the platform for recombinant protein-based
vaccine applications.
preparedness is a timely example of why Dyadic's platform matters," Emalfarb said. "But the opportunity is much broader.
The same capabilities being evaluated for outbreak preparedness are also being used to support commercial products across life sciences,
food, nutrition and industrial markets."
Adoption Expands Beyond Pandemic Preparedness
infectious disease preparedness provides a high-profile and urgent use case for Dyadic's technology, the Company is also leveraging
its protein production capabilities to commercialize recombinant proteins and enzymes across multiple markets.
commercial and development milestones include:
believes these programs demonstrate that its C1 and Dapibus platforms are not limited to one disease, one product or one market.
Instead, the Company is pursuing a diversified commercialization strategy that may include product sales, licensing, royalties, funded
collaborations, supply relationships and strategic partnerships.
Markets, Multiple Shots on Goal
C1 and Dapibus platforms are being developed to support recombinant protein production across several major categories:
and Pandemic Preparedness: vaccine antigens, monoclonal antibodies, infectious disease response and regional biologics manufacturing.
Sciences and Biomanufacturing: recombinant albumin, DNase I, transferrin, growth factors, diagnostics, cell culture media and bioprocessing
Nutrition and Wellness: animal-free proteins, dairy and other enzymes, precision fermentation ingredients and sustainable nutrition
Biotechnology: enzymes and specialty proteins for industrial processes, sustainability-focused manufacturing and bioindustrial applications.
Company believes this multi-market approach provides several potential pathways for long-term value creation while reducing dependence
on any single clinical program, outbreak event or commercial product.
Positioned at the Intersection of Global Health, AI and Scalable Protein Manufacturing
believes the convergence of emerging infectious disease preparedness, AI-enabled protein discovery, and growing demand for animal-free
and recombinant proteins is creating an opportunity for its scalable dual protein production platforms across global health and commercial
governments, global health organizations, biotechnology companies and academic institutions evaluate approaches to outbreak preparedness
and equitable access to biologics, Dyadic believes manufacturing capacity, scalability, speed and cost efficiency are becoming increasingly
important considerations.
makes this particularly exciting for Dyadic is that we have two complementary protein production platforms designed to serve distinct
but significant markets," Emalfarb said. "Our C1 platform is focused on life sciences and biopharmaceutical applications,
including pandemic preparedness, vaccine antigens, monoclonal antibodies, other biologics, diagnostics and cell culture inputs. Our Dapibus
platform is designed to support the commercialization of recombinant proteins and enzymes across food, nutrition, wellness and bioindustrial
markets, including animal-free ingredients, precision fermentation, specialty enzymes and industrial biotechnology applications. Together,
these platforms are targeting current addressable market opportunities that Dyadic estimates exceed $25 billion across life sciences,
food/nutrition, wellness and bioindustrial applications. As demand continues to grow for biologics, animal-free proteins, cell culture
inputs and industrial enzymes, we believe Dyadic's platforms are increasingly well positioned to support both global health initiatives
and commercial market opportunities."
Dyadic Applied BioSolutions
Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production
platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins
are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's proprietary Dapibus
and C1 expression systems support rapid, cost-effective, and flexible manufacturing.
more information, please visit http://www.dyadic.com.
Harbor Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events
or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research
projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be
identified by use of the words "expect," "should," "intend," "anticipate," "will,"
"project," "may," "might," "potential," or "continue" and other similar terms
or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking
information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking
information. Such statements reflect the current views of our management with respect to our operations, results of operations and future
financial performance. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic's control.
These factors include, but are not limited to (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein
production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies;